MoneyWorks4Me

Kopran - Quaterly Results

25 May 2023 Evaluate
The March 2023 quarter revenue stood at Rs. 802.28 millions, up 24.38% as compared to Rs. 645.03 millions during the corresponding quarter last year.Profit saw a slight increase of 15.61%to Rs. 55.18  millions from Rs. 47.73 millions.Operating profit for the quarter ended March 2023 rose to 94.37 millions as compared to 89.61 millions of corresponding quarter ended March 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 802.28 645.03 24.38 2730.95 2045.20 33.53 2730.95 2045.20 33.53
Other Income 20.74 22.80 -9.04 160.86 80.27 100.40 160.86 80.27 100.40
PBIDT 94.37 89.61 5.31 439.99 234.40 87.71 439.99 234.40 87.71
Interest 8.41 7.97 5.52 26.72 29.53 -9.52 26.72 29.53 -9.52
PBDT 85.96 81.64 5.29 413.27 204.87 101.72 413.27 204.87 101.72
Depreciation 10.89 10.61 2.64 44.12 43.23 2.06 44.12 43.23 2.06
PBT 75.07 71.03 5.69 369.15 161.64 128.38 369.15 161.64 128.38
TAX 19.89 23.30 -14.64 56.63 44.20 28.12 56.63 44.20 28.12
Deferred Tax 0.22 1.67 -86.83 -2.09 6.73 -131.05 -2.09 6.73 -131.05
PAT 55.18 47.73 15.61 312.52 117.44 166.11 312.52 117.44 166.11
Equity 482.12 482.12 0.00 482.12 482.12 0.00 482.12 482.12 0.00
PBIDTM(%) 11.76 13.89 -15.33 16.11 11.46 40.57 16.11 11.46 40.57
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..